Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer

Yoshioka, Takayuki; Hosoda, Mitsuchika; Yamamoto, Misazō; Taguchi, Kazunori; Hatanaka, Kanako C.; Takakuwa, Emi; Hatanaka, Yutaka; Matsuno, Yoshihiro; Yamashita, Hiroko

doi:10.1007/s12282-013-0474-2

Cited by 83 publications

(75 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our previous study showed that all patients whose tumors achieved pCR had good prognosis regardless of the breast cancer subtypes [6]. Our present study also demonstrates that all 6 patients whose tumors achieved pCR are currently disease-free.…”

Section: Discussionsupporting

confidence: 76%

“…Our previous study demonstrated that patients whose tumors contained high levels of Ki67 responded effectively to anthracycline and taxane-containing neoadjuvant chemotherapy [6].…”

Section: Discussionmentioning

confidence: 99%

“…Unfortunately, extensive subsets of patients do not experience pCR, even when treated with anthracyclins and taxanes [4,5]. Our previous study showed that the level of Ki67 labeling index (LI) in residual tumors after neoadjuvant chemotherapy was a strong predictor of outcome for patients not achieving pCR [6]. Minckwitz and colleagues also showed that patients with high posttreatment Ki67 levels (above 35%) showed higher risk of disease relapse in both ER-positive and ER-negative breast cancers [7].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer

M¹,

Takahashi²,

Yamashiro³

et al. 2015

Surg Today

Self Cite

View full text Add to dashboard Cite

2 AbstractPurpose Recent studies have indicated that constitutive NF-κB activity could be involved in the proliferation of triple-negative breast cancer. were not associated with response to neoaduvant chemotherapy, although expression levels of cytoplasmic NF-κB/p65 intensity were significantly decreased in post-treatment tumor samples compared with those in pretreatment samples. All patients whose tumors showed strong cytoplasmic NF-κB/p65 expression before neoadjuvant chemotherapy are currently disease-free. Methods ConclusionOur results suggest that strong cytoplasmic NF-κB/p65 expression could be a prognostic marker in triple-negative breast cancer.

show abstract

Section: Discussionsupporting

confidence: 76%

“…Our previous study demonstrated that patients whose tumors contained high levels of Ki67 responded effectively to anthracycline and taxane-containing neoadjuvant chemotherapy [6].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer

M¹,

Takahashi²,

Yamashiro³

et al. 2015

Surg Today

Self Cite

View full text Add to dashboard Cite

show abstract

“…Possible reasons of breast cancer mortality are tumor dormancy after treatment followed by local, regional or distant recurrence. Several factors as hormone receptors, HER2 status, proliferation fraction predicting outcome in preoperative setting were extensively examined in previous studies (Chen et al 2013;Denkert et al 2010;Lips et al 2013;Payne et al 2008;Teleki et al 2013;van Nes et al 2012;Varga et al 2005;Yoshioka et al 2013). The role of transcription factors (TF) in breast cancer prognosis has been the subject of some previous studies (Ablett et al 2012;Cimino-Mathews et al 2013;Giordano et al 2012;Guo et al 2012;Mego et al 2012).…”

Section: Introductionmentioning

confidence: 99%

Signaling Pathways in the Development of Infantile Hemangioma

2014

Cancer Cell Signaling

View full text Add to dashboard Cite

Background: Expression of transcription-factors as Slug and Sox9 was recently described to determine mammary stem-cell state. Sox10 was previously shown to be present also in breast cancer. Protein overexpression of Slug, Sox9 and Sox10 were associated with poor overall survival and with triple-negative phenotype in breast cancer. In this study we tested the stability of Slug, Sox9 and Sox10 expression during chemotherapy and addressed their prognostic role of in neoadjuvant treated primary breast-cancer and their correlation to pathological-response and overall survival. Methods: We analyzed immunohistochemical expression of Slug, Sox9 and Sox10 in tissue microarrays of 96 breast cancers prior to and after neoadjuvant chemotherapy. Expression was evaluated in invasive tumor cells and in tumor stroma and scored as 0, 1+, 2+ 3+. Expression-profile prior to and after chemotherapy was correlated to overall survival (Kaplan Meier) and with established clinico-pathological parameter.

show abstract

“…NACT also offers the clinician two significant information: response to treatment thus enabling the appropriate design of subsequent therapies and prognostic information for the patient. It is now acceptable that patients who achieve pathological complete response (pCR) after NACT appear to have significantly lower recurrence rate in comparison to those with residual disease upon surgery [19][20][21] . This is particularly true for patients with TNBC [20,22] and those with HER2-positive tumors treated with trastuzumab [21] .…”

Section: The Rationale Of Neoadjuvant Chemotherapy (Nact)mentioning

confidence: 99%

The recent progress of neoadjuvant chemotherapy in triple negative breast cancer: A short review

Liontos

Karageorgopoulou²,

Michalaki³

et al. 2015

JST

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) encompasses tumors that do not express either the estrogen receptor (ER) or the progesterone receptor (PR) and also do not overexpress the Human Epidermal growth factor Receptor 2 (HER2). This is a heterogenous group of tumors that significantly overlaps with both basal-like tumors and BRCA1/BRCA2 mutationassociated tumors. TNBC is highly aggressive in nature and exhibits worse prognosis than the other subtypes of breast cancer, despite its increased chemosensitivity. Neoadjuvant chemotherapy (NACT) is a treatment option regularly incorporated in clinical practice to improve subsequent surgical management. In parallel, allows rating of the pathological compete response (pCR) which is associated with the prognosis of these patients and evaluates the efficacy of the applied treatment as well. Platinum-based regimens and novel targeted therapies have shown some benefit in TNBC, though an unmet need for improved therapeutic strategies in this patient population still remains. In this review, the latest progresses in NACT in TNBC are discussed, along with the improved understanding of molecular targets and useful biomarkers in this group of patients.

show abstract

Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer

Abstract: Background: Recent studies have indicated that response to chemotherapy and the

Cited by 83 publications

References 24 publications

Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer

Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer

Signaling Pathways in the Development of Infantile Hemangioma

The recent progress of neoadjuvant chemotherapy in triple negative breast cancer: A short review

Contact Info

Product

Resources

About